Data Insights

Valemetostat by Daiichi Sankyo for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Valemetostat by Daiichi Sankyo for Non-Small Cell Lung Cancer: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Non-Small Cell Lung Cancer

Data Insights

Valemetostat by Daiichi Sankyo for Gastric Cancer: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Gastric Cancer

Data Insights

Valemetostat by Daiichi Sankyo for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

Valemetostat by Daiichi Sankyo for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

Valemetostat by Daiichi Sankyo for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...

Data Insights

Valemetostat by Daiichi Sankyo for Metastatic Renal Cell Carcinoma: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Metastatic Renal Cell Carcinoma. According to...

Data Insights

Valemetostat by Daiichi Sankyo for Non-Hodgkin Lymphoma: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...

Data Insights

Valemetostat by Daiichi Sankyo for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According...

Data Insights

Valemetostat by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Data Insights

Valemetostat by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase I for Metastatic Breast Cancer. According to GlobalData,...

Data Insights

Valemetostat by Daiichi Sankyo for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...